Clinical Trials Directory

Trials / Unknown

UnknownNCT05374954

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above

Safety and Immunogenicity Study on Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above Vaccinated the Prototype Inactivated COVID-19 Vaccine

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
4,200 (actual)
Sponsor
China National Biotec Group Company Limited · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with 2 or 3 doses of COVID-19 Vaccine (Vero Cell), Inactivated manufactured by Beijing Institute of Biological Products, Co., Ltd.

Detailed description

This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with 2 or 3 doses of COVID-19 Vaccine (Vero Cell), Inactivated manufactured by Beijing Institute of Biological Products, Co., Ltd. According to subject's age (18-59 vs 60 and above), doses of vaccination history ( 2 doses vs 3 doses), and vaccination interval, the subjects will be stratified and assigned randomly to the study groups ( Omicron inactivated COVID-19 Vaccine) or the control groups ( Prototype inactivated COVID-19 Vaccine) in a 2:1 ratio. All subjects will receive single dose or two doses of vaccine with a interval of 28 days. The occurrence of adverse events within 28 days and serious adverse events within 12 months after vaccination will be observed. The serum antibody levels, cellular immune responses will be analyzed at different time points.

Conditions

Interventions

TypeNameDescription
BIOLOGICALOmicron COVID-19 Vaccine (Vero Cell), Inactivatedintramuscular injection in the deltoid muscle
BIOLOGICALCOVID-19 Vaccine (Vero Cell), Inactivatedintramuscular injection in the deltoid muscle

Timeline

Start date
2022-05-10
Primary completion
2022-09-25
Completion
2023-11-10
First posted
2022-05-16
Last updated
2023-06-18

Locations

10 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05374954. Inclusion in this directory is not an endorsement.